EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Rheumatoid Arthritis: What Inflammation Do We Face?

Anastasia V. Poznyak, Tatyana Vladimirovna Kirichenko, Dmitry Felixovich Beloyartsev, Alexey V. Churov, Tatiana Ivanovna Kovyanova, Irina Alexandrovna Starodubtseva, Vasily N. Sukhorukov, Stanislav A. Antonov, Alexander N. Orekhov

Journal of Molecular Pathology · 08.10.2024 · 5 (4) · 454-465

DOI: 10.3390/jmp5040030 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Molecular Pathology, online erschienen am 08.10.2024. Verfasst von Anastasia V. Poznyak und 8 weiteren Autor:innen. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian Science Foundation.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by symmetrical joint inflammation, cartilage degradation, and bone erosion. This review explores the multifaceted aspects of RA pathogenesis, focusing on the dynamic interplay between innate and adaptive immune responses, genetic predisposition, and environmental triggers. The development of RA involves genetic susceptibility and trigger events such as infections, trauma, smoking, obesity, and microbiome alterations, fostering autoimmune reactions and tissue/organ destruction. The innate immune response, including toll-like receptor activation and synovial fibroblasts’ roles, contributes to the acceleration of inflammatory processes in joint tissues. Monocytes and macrophages organize and sustain chronic joint inflammation, leading to tissue damage and bone resorption, while highlighting the significance of CD14 and CD16 subsets in RA pathogenesis. In the adaptive immune response, aberrant activation and proliferation of CD4+ T cells and the role of regulatory T cells in maintaining immune tolerance are discussed. Target cytokines like TNF-α, IL-6, IL-1, IL-17, and BAFF, as well as chemokines such as CCL2, CXCL10, CCL5, and CXCL12, have emerged as critical components in managing chronic inflammation and joint damage in RA. This comprehensive overview provides insights into the pathophysiology of RA and potential therapeutic avenues, emphasizing the importance of understanding these complex immunological and genetic mechanisms for developing more effective treatment strategies.

Förderung

  • Russian Science Foundation

Zitieren

APA

Poznyak, A. V., Kirichenko, T. V., Beloyartsev, D. F., Churov, A. V., Kovyanova, T. I., Starodubtseva, I. A., Sukhorukov, V. N., Antonov, S. A., & Orekhov, A. N. (2024). Rheumatoid Arthritis: What Inflammation Do We Face?. Journal of Molecular Pathology, 5(4), 454-465. https://doi.org/10.3390/jmp5040030

Vancouver

Poznyak AV, Kirichenko TV, Beloyartsev DF, Churov AV, Kovyanova TI, Starodubtseva IA, et al. Rheumatoid Arthritis: What Inflammation Do We Face?. Journal of Molecular Pathology. 2024;5(4):454-465. doi:10.3390/jmp5040030

BibTeX
@article{Poznyak2024,
  author = {Poznyak, Anastasia V. and Kirichenko, Tatyana Vladimirovna and Beloyartsev, Dmitry Felixovich and Churov, Alexey V. and Kovyanova, Tatiana Ivanovna and Starodubtseva, Irina Alexandrovna and Sukhorukov, Vasily N. and Antonov, Stanislav A. and Orekhov, Alexander N.},
  title = {Rheumatoid Arthritis: What Inflammation Do We Face?},
  journal = {Journal of Molecular Pathology},
  year = {2024},
  volume = {5},
  number = {4},
  pages = {454--465},
  doi = {10.3390/jmp5040030}
}
Kostenlos starten →